MedTrace Logo

Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)

NCT05382208 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 133

Last updated 2026-01-26

No results posted yet for this study

Summary

The purpose of this study is to determine if doxycycline will reduce progression of emphysema in people living with HIV.

The secondary objectives are to examine the effects of doxycycline on change in quantity of emphysema, six minute walk distance, patient reported outcomes, ratio of forced expiratory volume in 1 second and forced vital capacity. Secondary objectives will also describe the safety and tolerability of doxycycline and determine if doxycycline is associated with development of antibiotic-resistant bacterial infections.

Conditions

  • Emphysema
  • HIV

Interventions

DRUG

Doxycycline

Doxycycline 100 mg orally twice a day.

DRUG

Placebo

Matching placebo orally twice a day.

Sponsors & Collaborators

Principal Investigators

  • Marshall J Glesby, MD, PhD · Weill Medical College of Cornell University

  • Cathie Spino, ScD · University of Michigan

  • Robert J Kaner, MD · Weill Medical College of Cornell University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-22
Primary Completion
2027-02-28
Completion
2027-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05382208 on ClinicalTrials.gov